Allergy Clinic, Casa della Salute, Genoa, Italy.
Allergy Clinic, Asl 2 Savona, Savona, Italy.
Eur Ann Allergy Clin Immunol. 2021 Jul;53(4):171-176. doi: 10.23822/EurAnnACI.1764-1489.164. Epub 2020 Jul 30.
Different clinical pictures are related to corticosteroids (CS) non immediate hypersensitivity and the frequency of these reactions can be underestimated. The classification of CS in 3 groups and the identification of two patient's profiles has been proposed by Baeck to help clinicians in the management of these cases. Data of 14 patients with clinical history of delayed reactions to various CS and positive skin test and/or oral challenge are retrospectively analyzed. Three different patterns of patients are identified evaluating history, clinical picture and tests results. The first one (6 pts, 43%) is characterized by cutaneous and/or mucosal reaction due to inhaled Budesonide and patch test positive only to topical molecules belonging to the group 1 of CS. The second pattern (4 pts) has clinical history of local and systemic skin reactions to the topic and parenteral administration of the same or other steroid drugs. Patients belonging to the third pattern (4 pts) have a history of systemic reactions to general administration of CS without previous contact reaction. Pattern 2 and 3 show a wide sensitization to molecules belonging to the 3 groups of CS. All the patients show patch test positive to Budesonide. Although the lack of standardization, the allergy workup proves useful to differentiate patients sensitized to one or few molecules from polysensitized and to identify the culprit drugs. Intradermal and challenge test are necessary to complete the diagnostic workup. The results suggest the possibility of a different management of patients. Patients of pattern one can be only patch tested with a limited series of CS belonging to the 3 groups. They don't need an extensive exclusion of steroids use. The pattern 2 and 3 must be submitted instead to a complete allergological individual evaluation to identify alternative tolerated drugs, because of the risk of systemic reactions. The Baeck's classification shows limited usefulness in these cases.
不同的临床症状与皮质类固醇(CS)非即刻过敏有关,这些反应的频率可能被低估。Baeck 提出将 CS 分为 3 组,并确定两种患者特征,以帮助临床医生管理这些病例。
回顾性分析了 14 例有各种 CS 延迟反应史、皮肤试验和/或口服挑战阳性的患者资料。根据病史、临床表现和检查结果,确定了 3 种不同类型的患者。第一种(6 例,43%)表现为因吸入布地奈德而出现的皮肤和/或黏膜反应,且斑贴试验仅对属于 CS 第 1 组的局部用分子呈阳性。第二种模式(4 例)有局部和全身皮肤对局部和全身应用相同或其他类固醇药物的局部和全身皮肤反应史。属于第三种模式(4 例)的患者有全身应用 CS 后无先前接触反应的全身反应史。模式 2 和 3 对属于 CS 第 3 组的分子有广泛的致敏性。所有患者对布地奈德斑贴试验均呈阳性。
尽管缺乏标准化,但过敏检查有助于区分对一种或几种分子敏感的患者与多敏患者,并确定罪魁祸首药物。皮内和挑战试验是完成诊断工作的必要条件。结果表明,患者的管理方式可能存在差异。模式 1 的患者仅需用有限系列的 CS(属于 3 组)进行斑贴试验。他们不需要广泛排除类固醇的使用。模式 2 和 3 必须进行完整的过敏个体化评估,以识别替代耐受药物,因为存在全身反应的风险。在这些情况下,Baeck 的分类显示出有限的用途。